Helix Biopharma Q2 2026 Earnings Results & Report

Helix Biopharma EPS Results

• Actual EPS: -$0.01
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Helix Biopharma Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Helix Biopharma (OTCMKTS:HBPCF) is a Canadian clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. The company’s research is centered on treatments designed to act within the tumor microenvironment, with the goal of improving the effectiveness of oncology medicines.

Its lead product candidate is L-DOS47, an antibody-enzyme conjugate designed to target CEACAM6, a protein expressed on the surface of certain cancer cells. L-DOS47 combines a targeting antibody fragment with urease, an enzyme intended to generate ammonia in the tumor environment and potentially disrupt conditions that support tumor growth. The candidate has been evaluated in clinical development for cancers including pancreatic adenocarcinoma and non-small cell lung cancer.

Helix BioPharma is based in Canada and has historically focused its development activities on oncology programs intended for international clinical and commercial markets. As a development-stage biotechnology company, its operations and future prospects depend on the progress of its drug candidates through clinical testing, regulatory review and potential commercialization.